An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-Dose Interferon on Progression-Free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Trial Profile

An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-Dose Interferon on Progression-Free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 May 2015 Primary and secondary endpoints are amended.
    • 14 Jan 2013 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top